
What is claimed is:

1. A composition for use in treating retinal diseases in a subject comprising a therapeutically effective amount of a composition comprising a compound having Formula I, its individual enantiomers, its individual diastereoisomers, its hydrates, its solvates, its crystal forms, its individual isomers, its individual tautomers or a pharmaceutically acceptable salt thereof,



Formula I

wherein

R^1 is H or C_{1-3} alkyl;


R^2 is H or C_{1-3} alkyl;

R^3 is H, C_{1-10} alkyl, heterocycle or aryl; and

R is C_{1-10} alkyl, heterocycle or aryl; and

wherein the retinal disease is selected from the group consisting of age related macular degeneration, wet macular degeneration, dry macular degeneration, geographic atrophy, diabetic retinopathy, diabetic macular edema and retinal vein occlusion.

2. A composition according to claim 1 wherein the compound is of Formula II, its individual diastereoisomers, its hydrates, its solvates, its crystal forms, its individual isomers, its individual tautomers or a pharmaceutically acceptable salt thereof,



Formula II

wherein

R^1 is H or C_{1-3} alkyl;

R^2 is H or C_{1-3} alkyl;


R^3 is H, C_{1-10} alkyl, heterocycle or aryl; and

R is C_{1-10} alkyl, heterocycle or aryl.

2-*tert*-Butoxycarbonylamino-3-phenyl-propionic acid 3-[(*S*)-1-(1*H*-imidazol-4-yl)-ethyl]-2-methyl-benzyl ester.

~~8. A retinal disease according to claim 1 selected from: age related macular degeneration, wet macular degeneration, dry macular degeneration, geographic atrophy, diabetic retinopathy, diabetic macular edema and retinal vein occlusion. Our compound of interest is also useful for enhancing vision in patients with vision loss from conditions including ocular hypertension, glaucoma, retinitis pigmentosa, nyctalopia, and neuritis secondary to multiple sclerosis.~~

~~9. An article of manufacture comprising packaging material and a pharmaceutical agent contained within said packaging material, wherein the pharmaceutical agent is therapeutically effective for treating retinal diseases and wherein the packaging material comprises a label which indicates the pharmaceutical agent can be used for treating retinal diseases and wherein said pharmaceutical agent comprises an effective amount of compound is of Formula II, its individual diastereoisomers, its hydrates, its solvates, its crystal forms, its individual isomers, its individual tautomers or a pharmaceutically acceptable salt thereof,~~



~~Formula II~~

~~wherein~~


~~R^1 is H or C_{1-3} alkyl;~~

~~R^2 is H or C_{1-3} alkyl;~~

~~R^3 is H, C_{1-10} alkyl, heterocycle or aryl; and~~

~~R is C_{1-10} alkyl, heterocycle or aryl.~~

~~10.~~8. A pharmaceutical composition for treating retinal diseases~~s~~ in a subject comprising a compound having a structure



Formula II

wherein

R^1 is H or C_{1-3} alkyl;

R^2 is H or C_{1-3} alkyl;

R^3 is H, C_{1-10} alkyl, heterocycle or aryl; and

R is C_{1-10} alkyl, heterocycle or aryl; and

wherein the retinal disease is selected from the group consisting of age related macular degeneration, wet macular degeneration, dry macular degeneration, geographic atrophy, diabetic retinopathy, diabetic macular edema and retinal vein occlusion.

~~11.~~9. The pharmaceutical composition of claim ~~10~~ 8 wherein the compound is selected from:

iso-Butyric acid 3-[(*S*)-1-(1*H*-imidazol-4-yl)-ethyl]-2-methyl-benzyl ester;

2,2-Dimethyl-propionic acid 3-[(*S*)-1-(1*H*-imidazol-4-yl)-ethyl]-2-methyl-benzyl ester;

Acetic acid 3-[(*S*)-1-(1*H*-imidazol-4-yl)-ethyl]-2-methyl-benzyl ester;

Benzoic acid 3-[(*S*)-1-(1*H*-imidazol-4-yl)-ethyl]-2-methyl-benzyl ester;

3-Methyl-butyric acid 3-[(*S*)-1-(1*H*-imidazol-4-yl)-ethyl]-2-methyl-benzyl ester;

3-Phenyl-propionic acid 3-[(*S*)-1-(1*H*-imidazol-4-yl)-ethyl]-2-methyl-benzyl ester;

2-Amino-3-methyl-butyric acid 3-[(*S*)-1-(1*H*-imidazol-4-yl)-ethyl]-2-methyl-benzyl ester;

2-(2-Amino-3-methyl-butyrylamino)-3-methyl-butyric acid 3-[(*S*)-1-(1*H*-imidazol-4-yl)-ethyl]-2-methyl-benzyl ester;

2-(2-Amino-acetylamino)-3-methyl-butyric acid 3-[(*S*)-1-(1*H*-imidazol-4-yl)-ethyl]-2-methyl-benzyl ester; and

2-Amino-3-phenyl-propionic acid 3-[(*S*)-1-(1*H*-imidazol-4-yl)-ethyl]-2-methyl-benzyl ester.